Omega 3 fatty acid formulations

Abstract

The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.

1 - 24 . (canceled) 
     
     
         25 . A method of treating cardiovascular disease, depression, and inflammatory disorders by providing an effective amount of a formulation to a patient in need thereof, said formulation comprising eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) in a weight to weight ratio of about 5:1 to about 6.99:1, and wherein the formulation is more than 84% EPA and DHA by weight. 
     
     
         26 . The method of  claim 25 , wherein the EPA and DHA are in the ethyl ester form. 
     
     
         27 . The method of  claim 25 , wherein said formulation is provided in a unit dosage form comprising at least 100 mg DHA and at least 400 mg EPA. 
     
     
         28 . The method of  claim 25 , wherein said formulation is provided in a unit dosage form comprising at least 125 mg DHA and 600 mg EPA. 
     
     
         29 . The method of  claim 25 , wherein the formulation additionally comprises a stabilizer. 
     
     
         30 . The method of  claim 29 , wherein the stabilizer is vitamin E. 
     
     
         31 . The method of  claim 25 , wherein the formulation is more than 90% omega-3 fatty acids by weight. 
     
     
         32 . The method of  claim 25 , wherein the formulation comprises less than 1% cholesterol. 
     
     
         33 . The method of  claim 25 , wherein the formulation comprises less than 10 meq/kg peroxides. 
     
     
         34 . The method of  claim 25 , wherein the cardiovascular disease is hypertriglyceridemia or low HDL. 
     
     
         35 . The method of  claim 25 , wherein the formulation is consisting essentially of omega-3 fatty acids. 
     
     
         36 . The method of  claim 36 , wherein 750 to 3000 mg of the formulation are provided to said patient daily. 
     
     
         37 . A pharmaceutical product, comprising a formulation in a package together with instructions for using the formulation to treat a cardiovascular disorder, depression, and inflammatory disorder, wherein said formulation comprises eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) in a weight to weight ratio of about 5:1 to about 6.99:1, and wherein the formulation is more than 84% EPA and DHA by weight. 
     
     
         38 . The pharmaceutical product of  claim 37 , wherein the formulation has a dosage form of a gel or liquid capsule and is packaged in blister packages of about 20 capsules per sheet. 
     
     
         39 . The pharmaceutical product of  claim 37 , wherein the formulation is consisting essentially of omega-3 fatty acids.